AEG

Aegis Life is a clinical-stage biotechnology company focused on developing next-generation DNA and RNA vaccines and therapeutics for infectious diseases and oncology. Spun out of Entos Pharmaceuticals, the company utilizes the proprietary Fusogenix proteo-lipid vehicle (PLV) platform, which enables the efficient delivery of genetic medicines directly into target cells. Their lead candidate, Aegis-CoV-001, is a DNA-based vaccine designed to provide robust and long-lasting immunity against COVID-19. By leveraging a non-viral delivery system, Aegis Life aims to overcome the limitations of traditional viral vectors and current mRNA technologies, such as stability and manufacturing scalability. The company's pipeline also includes programs targeting Hepatitis B and other high-burden global health challenges.